It is the first oral Janus kinase (JAK) inhibitor indicated for acute treatment and maintenance therapy in both Crohn's disease and ulcerative colitis in adults.
Researchers examined a random sample of health insurance claim records of 16 million patients in the United States between 2006 and 2020 for use of semaglutide drugs.